(RTTNews) - Halozyme Therapeutics (HALO) reiterated full year 2024 financial guidance and increased full year 2025 and multi-year financial guidance. For 2025, the company now expects: non-GAAP EPS in a range of $4.95 to $5.35, revised from prior guidance range of $4.45 to $4.85. Total revenue is now expected in a range of $1.15 billion to $1.225 billion, revised from prior guidance range of $1.095 billion to $1.17 billion.
Preliminary estimates of results for the twelve months ended December 31, 2024, include: Non-GAAP EPS in a range of $4.00 to $4.20; and total revenue in a range of $970 million to $1.02 billion.
The company also announced it has recently entered into a new $250 million accelerated share repurchase program under previously announced $750 million share repurchase program.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
